Why you might not be losing weight on 1.7mg Wegovy

Is 1.7mg actually meant to be where the weight loss happens?

The short answer is: not always. Wegovy's dosing schedule (0.25mg, 0.5mg, 1.0mg, 1.7mg, then 2.4mg) exists for a specific reason. The earlier doses, including 1.7mg, are primarily about building tolerability, letting your system adjust to semaglutide's effects before reaching the therapeutic maintenance dose of 2.4mg. The full Wegovy dose schedule is designed so that most people spend roughly four weeks at each level before moving up.

The landmark STEP 1 trial, published in the New England Journal of Medicine, recorded an average body weight reduction of around 15% over 68 weeks, but participants were maintained at 2.4mg for the bulk of that period. Data collected while patients were still at intermediate doses looked considerably more modest. So if your scale is underwhelming you right now, the 2.4mg step may be where the real shift occurs.

That's not a guarantee, weight loss is never linear, and the rate of progress slows as the weeks pass regardless of dose. But it does mean that drawing firm conclusions about whether Wegovy is working for you at 1.7mg may be premature. Your prescriber is best placed to assess whether the timing of your titration makes sense.

What else could be limiting your results on 1.7mg?

Semaglutide reduces appetite and slows gastric emptying, but it works alongside your habits rather than instead of them. If calorie intake has crept back up (perhaps because nausea from earlier doses has eased and eating has become comfortable again) the medicine's appetite-suppressing effect may not be enough on its own to create the deficit needed for consistent weight loss. A question our prescribers hear fairly regularly: "I feel less hungry but I still seem to eat the same amount." That shift in hunger signalling takes time, and eating speed, food choices and meal structure all still matter.

Protein intake is worth looking at specifically. On a GLP-1 medicine, total food intake tends to fall, and if protein falls with it, the body may be losing muscle alongside fat, which slows the metabolic rate and makes further loss harder. NHS guidance on healthy weight gives a useful baseline for balanced eating, though a dietitian can offer personalised support.

Sleep is another underrated factor. Poor sleep raises hunger hormones independently of what semaglutide is doing, which can directly counteract appetite suppression. And resistance-based activity (not necessarily intense gym sessions, but anything that preserves muscle) helps maintain the metabolic conditions for fat loss. For practical ideas on getting more from your treatment, the five ways to boost weight loss on Wegovy covers these levers in detail.

Could something else be working against the medicine?

Sometimes the issue is biological rather than behavioural. Thyroid conditions (particularly underactive thyroid (hypothyroidism)) can significantly blunt weight loss and are easy to miss if they haven't been recently tested. Certain medicines, including some antidepressants, antipsychotics, corticosteroids and beta-blockers, are associated with weight gain or resistance to weight loss, and their interaction with semaglutide's effects is a legitimate clinical consideration worth raising with your GP or prescriber.

Stress and elevated cortisol can also encourage fat retention around the abdomen, even when other habits are sound. This isn't about willpower, it's physiology, and it's the kind of context that matters when a prescriber reviews your progress. If you're not already getting that regular review, it's one of the reasons a structured service matters. At nume (sorry, at

At the service we run at nume, a real clinician reviews your case before every repeat order) not a form that auto-approves. That means patterns like these get noticed. It's also worth checking the frequently asked questions if you have general queries about the treatment process.

When should you consider moving to 2.4mg, or reviewing your treatment?

If you've been on 1.7mg for four weeks, tolerated it reasonably well and haven't seen meaningful progress, the natural next conversation is whether moving to the 2.4mg maintenance dose is appropriate. The clinical trial data, and NICE's recommendation for semaglutide (TA875), centre on 2.4mg as the therapeutic dose for weight management. Reaching it is the goal, not a bonus.

That said, if you're experiencing significant nausea or other side effects at 1.7mg, your prescriber might suggest staying at this dose for an additional four weeks before moving up. The titration schedule is a guide, not a rigid timetable, toleration matters more than speed. If 2.4mg has been your dose for several months and progress has genuinely stalled, the calculus changes. The guidance on stalling at 2.4mg covers that scenario separately.

Some people find a lot of reassurance in understanding at which point most people begin to see results on Wegovy. Weight loss timelines vary considerably person to person, and comparing your week eight to someone else's week twelve usually isn't helpful. If you're earlier in your titration and wondering whether things should be moving faster, our separate guides on why weight loss can feel slow at the 0.5mg stage and what to make of limited progress at 1mg may give useful context for where you are in the journey. What matters is the trend over weeks, not days, and your prescriber's assessment of where you are in the process. If you're ready to have that conversation and want clinical input on your next step, checking your eligibility with our prescribers is a straightforward starting point.